(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/133278 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2021/064145

(22) International Filing Date:
17 December 2021 (17.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/127,616 18 December 2020 (18.12.2020) US

(71) Applicant: **IONIS PHARMACEUTICALS, INC.** [US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: **FREIER, Susan, M.**; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **BUI, Huynh-Hoa**; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **ZHAO, Chenguang**; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **MONIA, Brett, P.**; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **CROSBY, Jeffrey, R.**; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Ct., Carlsbad, CA 92010 (US).

(74) Agent: **GINGRICH, Brenden** et al.; Knobbe Martens LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2022/133278 A2

(54) Title: COMPOUNDS AND METHODS FOR MODULATING FACTOR XII

(57) Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXII RNA in a cell or subject, and in certain instances reducing the amount of FXII protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of a thromboembolic condition. Such thromboembolic conditions include deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, and stroke. Such symptoms include pain, shortness of breath, heart burn, cold sweat, fatigue, lightheadedness, dizziness, swelling, cramping, and death. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of hereditary angioedema.